Table 2.
IC50 values for AZD9291, with or without crizotinib or c‐Met mAb, against the proliferation of parental and resistant HCC827 cells
| Cell line | IC50 (mean ± SD)a | ||||
|---|---|---|---|---|---|
| AZD9291 (nmol/L) | Crizotinib (nmol/L) | AZD9291 (nmol/L, + 100 nmol/L crizotinib) | c‐Met mAb (ng/mL) | AZD9291 (nmol/L, + 1 μg/mL c‐Met mAb) | |
| HCC827 | 2.6 ± 0.3 | 3853.0 ± 858.4 | 4.0 ± 1.3 | >30 000.0 | 2.3 ± 0.2 |
| HA1 | 5002.5 ± 509.8 (1924.0)b | 2929.5 ± 105.4 | 111.6 ± 25.8 (27.9)b | >30 000.0 | 2753.5 ± 279.3 (1197.2)b |
| HA2 | 1086.5 ± 81.3 (417.9)b | 3864.0 ± 722.7 | 291.1 ± 86.5 (72.8)b | >30 000.0 | 1163.5 ± 3.5 (505.9)b |
| HG1 | 119.4 ± 25.9 (45.9)b | 2056.5 ± 99.7 | 130.0 ± 50.4 (32.5)b | >30 000.0 | 148.9 ± 19.1 (64.7)b |
| HG2 | 1111.5 ± 26.2 (427.5)b | 3740.0 ± 196.6 | 877.0 ± 138.8 (219.3)b | >30 000.0 | 2059.5 ± 392.4 (895.4)b |
| HG3 | 124.8 ± 6.3 (48.0)b | 2134.0 ± 567.1 | 146.0 ± 22.4 (36.5)b | >30 000.0 | 488.8 ± 71.4 (212.5)b |
| HG4 | 511.9 ± 2.8 (196.9)b | 3217.5 ± 54.5 | 538.8 ± 2.2 (134.7)b | >30 000.0 | 1639.5 ± 150.6 (712.8)b |
Abbreviation: c‐Met mAb, c‐mesenchymal‐epithelial transition factor‐targeting monoclonal antibody.
a
IC50 were determined using sulforhodamine B assays by treating cells with different concentrations of drugs for 72 h. Data are presented as means ± SD of three independent experiments.
b
Resistance ratio = IC50 (resistant cells)/IC50 (HCC827).